The End­points poll: A large ma­jor­i­ty of bio­phar­ma ex­ecs turn thumbs down on Bio­gen's con­tro­ver­sial pitch for ad­u­canum­ab

There’s a big vote loom­ing at the end of the week as out­side ex­perts at the FDA put Bio­gen’s Alzheimer’s drug ad­u­canum­ab on tri­al. But as far as the in­dus­try is con­cerned, most peo­ple in bio­phar­ma have al­ready made up their minds. And they’re turn­ing thumbs down on that drug in large num­bers.

More than a thou­sand peo­ple took our snap poll on the pan­el de­ci­sion com­ing on Fri­day, and 63% of them say the pan­el will vote to re­ject Bio­gen’s bid to gain an ap­proval on mixed da­ta from two late-stage stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER